State Grid has initiated the establishment of 28 international standards
Time of Update: 2022-11-21
International standardsShu Yinbiao, chairman of the State Grid Corporation and vice chairman of the IEC, said that the State Grid led the establishment of four IEC new technical committees for high-voltage direct current transmission, smart grid user interface, renewable energy access to the grid and UHV AC system, which will further promote technological innovation and industrial upgrading of China's and even the global energy and power industry.
EU CHMP gives green light to two CAR-T therapies, Carvykti and Kymriah
Time of Update: 2022-04-23
CAR-T lymphomaSpecifically, the CHMP recommends Carvykti for the treatment of adults with relapsed/refractory (r/r) multiple myeloma who have received at least three prior therapies, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies .
The world's largest caprolactam-nylon integrated project is fully promoted in Fujian
Time of Update: 2021-12-09
At present, in the New Chemical Materials Industrial Park of Kemen Port Economic Zone, the second phase of Shenyuan's 400,000 tons of polyamide integration project is stepping up construction, and one of the 200,000 tons of caprolactam production line has been put into operation.
Announcement of Phase I study of Hebo Pharma's new-generation anti-CTLA-4 antibody HBM4003
Time of Update: 2021-10-23
On September 13, Harmonicare announced that its self-developed product HBM4003 has achieved positive results in a phase I dose-climbing clinical trial for patients with advanced solid tumors in Australia .
The Phase I study is an open-label, multi-center study conducted in subjects with advanced solid tumors.
Sinopharm China Biotech Wuhan Institute of New Crown Vaccine Releases Interim Analysis Data of Phase III Clinical Trial
Time of Update: 2021-07-25
According to statistical analysis, the results of the interim analysis of the phase III clinical trial showed that the safety of the new coronavirus inactivated vaccine from the Wuhan Institute of Biological Products of Sinopharm Group was good.
Dezhan Health: VGX-3100 Project Phase III Trial Reached the Primary Endpoint and All Secondary Endpoints
Time of Update: 2021-07-21
The positive results of the first phase III clinical trial (REVEAL1) of the combination of the drug VGX-3100 and the device CELLECTRATM5PSP in the treatment of HPV-16/18-related high-grade cervical squamous intraepithelial lesions (HSIL), reached the clinical level in all evaluable subjects The primary endpoint of efficacy and all secondary endpoints .
Potential "first-in-class" oral antidepressants reach phase 3 clinical endpoints
Time of Update: 2021-06-30
On June 15, 2021, Sage Therapeutics and Biogen jointly announced that the potential "first-in-class" oral drug zuranolone (SAGE-217/BIIB125) for patients with major depression (MDD) is in a phase 3 clinical trial The primary end point was reached .
In response to virus mutation, inactivated vaccines have better broad-spectrum
Time of Update: 2021-06-04
Inactivated vaccines are used more in my countryDoes the current new crown vaccine have any effect on virus mutation?Zhang Yuntao, vice president of Sinopharm Group China Biology, introduced at the press conference that virus mutation is an issue that has received high attention during the development and use of vaccines.
Oncologist: The efficacy and safety of cimiprizumab+radiotherapy+cyclophosphamide+GM-CSF in the treatment of recurrent/metastatic head and neck squamous cell carcinoma
Time of Update: 2021-05-20
Cimiprizumab combined with radiotherapy, cyclophosphamide and granulocyte macrophage colony stimulating factor (GM-CSF) is not as effective as other PD-1 inhibitors in patients with refractory/metastatic head and neck squamous cell carcinoma Monotherapy.
AstraZeneca announces phase 3 clinical trial of its new crown vaccine confirms safety and effectiveness
Time of Update: 2021-04-27
On March 25, AstraZeneca announced that the main analysis of the Phase 3 clinical trial of the new crown vaccine AZD1222 has obtained high-level positive results. The results confirmed that its effec
How to treat PD-1 incurable eye melanoma? Anti-CD40 antibody YH003 in union with Toripalimab
Time of Update: 2021-02-11
The trial is a multi-center, open-label study with a multi-dose upgrade phase designed to assess the safety, tolerance, pharmacogenetics and initial efficacy of YH003 in the joint treatment of advanced solid tumors with Toripalimab; for example, a 68-year-old woman with eye melanoma and liver metastasis is resistant to a joint protocol of first-line Nivolumab (anti-PD-1 antibody) and second-line Nivolumab/Ipilimumab (anti-CTLA-4 antibody).
The Roche Tecentriq/Avastin combination improves the overall survival of hepatocellular carcinoma
Time of Update: 2021-01-25
In response, Levi Garraway, Roche's chief medical officer and head of global product development, said the results showed that Tecentriq and Avastin's Phase III trial results showed that patients reached the longest survival rate in non-removable hepatocellular carcinoma first-line treatment, a combination that has now been approved by regulators in more than 60 countries and regions around the world, meaning the combination has helped make significant progress in treating this malignant tumor.
Jia and biopharmacemics "Invlisi monoanti" biosynthic drugs declared on the market
Time of Update: 2021-01-11
The new drug application is based on a three-stage trial of randomized, double-blind, parallel control in China to assess the safety and efficacy of GB242 contrast grams (Invlisi monoantigen) and methotrexate combined at a dose of 3 mg/kg intravenously treated patients with rheumatoid arthritis.
WHO: The new coronavirus is still spreading rapidly
Time of Update: 2020-11-27
, June 19 (Xinhua Liu Qu) The World Health Organization said on the 19th that the new coronavirus is still spreading rapidly around the world, countries to prevent the possibility of new outbreaks peak.
GlaxoSmithKline M72/AS01E candidate vaccine gets positive results in Phase 2b clinical trial
Time of Update: 2020-06-11
tuberculosis is one of the leading causes of infectious disease death worldwide It is estimated that one quarter of the world's population is infected with latent tuberculosis, in which case mycobact